Akero Therapeutics Inc

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Here is how Akero Therapeutics, Inc. (AKRO) and Accelerate Diagnostics (AXDX) have performed compared to their sector so far this year.

Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?

Akero Therapeutics is making strong progress in developing a treatment for NASH, an area of high unmet medical need. The company's lead product candidate has shown promising and highly significant results in Phase 2b trials for NASH, primary and secondary endpoints. Akero Therapeutics' recent Phase 2b expansion cohort study demonstrated that EFX, when added to a weight loss agonist, delivered significantly improved results.

Akero Therapeutics: Marching On And Delivering Promising Results

C3.ai

Joby Aviation

There have been plenty of headlines in recent weeks regarding the influence a few tech titans are having on the broader market rally that's underway, with some voices suggesting the S&P 500 would actually be down for the year if it were not for their outperformance.

3 Mid Caps You Haven't Heard Of But Need To Know About

Akero Therapeutics, Inc. (AKRO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Akero Therapeutics, Inc. (AKRO) Is a Great Choice for 'Trend' Investors, Here's Why

Akero Therapeutics Inc said on Monday data from a mid-stage study showed its experimental therapy reduced liver fat by 65% in certain patients with a type of fatty liver disease called nonalcoholic steatohepatitis (NASH).

Akero says NASH drug shown to reduce liver fat by 65% in some patients

Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone

Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease

Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1

SAN FRANCISCO, May 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that management will present at the Jefferies Healthcare Conference Wednesday, June 7, 2023, at 10:30 a.m. (ET) in New York, NY.

Akero Therapeutics to Present at the Jefferies Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 29.2% in Akero Therapeutics, Inc. (AKRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Akero Therapeutics, Inc. (AKRO)? Wall Street Analysts Think 29.22%

Strong clinical results, including significant reductions in liver fat, improvements in glycemic control, and fibrosis regression without worsening of NASH, support the efficacy and potential of EFX. Akero Therapeutics' ongoing Phase 2b and Phase 3 trials highlight its commitment to advancing its clinical programs and capturing a substantial share of the NASH market.

Akero Therapeutics: A Promising Solution For NASH Patients And Investors

SOUTH SAN FRANCISCO, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the pricing of an underwritten offering of 5,238,500 shares of its common stock at a price of $42.00 per share, before deducting underwriting discounts and commissions, for total gross proceeds of approximately $220.0 million. All of the shares to be sold in the offering are being sold by Akero Therapeutics. The financing was led by new investor General Atlantic and included existing investors Adage Capital Partners LP, Avidity Partners, Boxer Capital, Commodore Capital, Janus Henderson Investors, Logos Capital, Perceptive Advisors, Rock Springs Capital and funds and accounts advised by T. Rowe Price Associates, Inc. The offering is expected to close on or about May 19, 2023, subject to the satisfaction of customary closing conditions.

Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

-- Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, to be reported during the second quarter of 2023 -- -- SYNCHRONY Phase 3 studies on track to begin enrolling in the second half of this year --

Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

If you are looking for stocks that are well positioned to maintain their recent uptrend, Akero Therapeutics, Inc. (AKRO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in Akero Therapeutics, Inc. (AKRO) Should Keep going

Akero Therapeutics has a proof of concept in using EFX for the treatment of patients with NASH Fibrosis established in the phase 2b HARMONY study. Results from cohort D of phase 2b SYMMETRY study using EFX on top of existing GLP-1 receptor agonist therapy to treat patients with pre-cirrhotic NASH and T2D expected Q2 2023.

Akero Therapeutics: Proof Of Concept With EFX, Sets Up Catalyst Opportunities In 2023

AKRO will produce phase 2b SYMMETRY data in 4Q, but phase 3 will be a few years away. I believe Madrigal's success and the far off phase 3 may dampen exuberance around SYMMETRY.

Akero Therapeutics: Excellent Data, Solid Clinical Potential, No Major Near Term Catalysts

Akero Therapeutics (AKRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Akero Therapeutics (AKRO)

The consensus price target hints at a 42.6% upside potential for Akero Therapeutics, Inc. (AKRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Akero Therapeutics, Inc. (AKRO) Climb 42.57% to Reach the Level Wall Street Analysts Expect?

89bio Inc

Intercept Pharma

Eli Lilly

Madrigal Pharmaceuticals

Novo Nordisk

Pfizer

Terns Pharmaceuticals

Viking Therapeutics

NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH

The planned Phase 3 program consists of three trials, SYNCHRONY Histology , SYNCHRONY Real-World , and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NASH

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2022.

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy.

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA.

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Results of the main study in patients with compensated cirrhosis due to NASH (F4) expected in fourth quarter of 2023

Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones

Designation based on Akero's Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks Designation based on Akero's Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks

Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH

In September, AKRO went up on solid phase 2b data. MDGL, which also has strong phase 2 data, is toplining phase 3 by next month but has a lower valuation.

News for Akero Therapeutics Inc Stock (AKRO)